Gestational Diabetes Market

Name: Gestational Diabetes Market Size, Share & Trends Report 2035
Brand: Market Research Future
Price: 4950.0 USD
Availability: InStock

Gestational Diabetes Market Research Report By Diagnosis Type (Oral Glucose Tolerance Test, Fasting Blood Sugar Test, Random Blood Sugar Test, Hemoglobin A1c Test), By Treatment Type (Dietary Changes, Insulin Therapy, Oral Medications, Physical Activity), By Risk Factor (Obesity, Family History, Age, Previous Gestational Diabetes), By Patient Age (Teenagers, Adults, Elderly) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

ID: MRFR/Pharma/3172-HCR 90 Pages Vikita Thakur, Rahul Gotadki Last Updated: September 10, 2026

Gestational Diabetes Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.81%

2024 Market Size$ 1.99 Billion

2025 Market Size$ 2.11 Billion

2035 Market Size$ 3.7 Billion

Key Players

Companies such as Abbott Laboratories

Roche Diagnostics

Becton Dickinson and Company

Medtronic

Dexcom

Ascensia Diabetes Care

Trends

Technological Advancements in Monitoring
Increased Focus on Preventive Care
Integration of Telehealth Services

Opportunities

Advancements in Medical Technology
Increase in Healthcare Expenditure
Policy Changes and Healthcare Reforms

Request Free Sample

Gestational Diabetes Market Summary

According to MRFR analysis, the Gestational Diabetes Market Size was valued at USD 1.99 Billion in 2024. The market is projected to grow from USD 2.106 Billion in 2025 to USD 3.704 Billion by 2035, registering a CAGR of 5.81% during the forecast 2025–2035. North America led the market with over 45.23% share, generating around USD 0.9 billion in revenue.

The Microsurgery Market is expanding due to rising demand for minimally invasive surgical procedures and increasing prevalence of chronic and complex conditions. Key trends include advancements in robotic-assisted microsurgery, high-precision surgical instruments, improved imaging technologies, and growing adoption across specialties such as neurosurgery, ophthalmology, and reconstructive surgery.

According to the World Health Organization, noncommunicable diseases account for over 70% of global deaths, increasing the need for advanced surgical interventions.

Key Market Trends & Highlights

The Gestational Diabetes Market is experiencing notable growth driven by technological advancements and increased awareness.

Technological advancements in monitoring are enhancing patient care and management in the Gestational Diabetes Market.
North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region for gestational diabetes solutions.
The Oral Glucose Tolerance Test continues to dominate the market, whereas the Hemoglobin A1c Test is witnessing rapid growth.
Rising incidence of gestational diabetes and advancements in medical technology are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size	1.99 (USD Billion)
2035 Market Size	3.704 (USD Billion)
CAGR (2025 - 2035)	5.81%

Major Players

Companies such as Abbott Laboratories(US), Roche Diagnostics (CH), Becton Dickinson and Company (US), Medtronic (US), Dexcom (US), Ascensia Diabetes Care (DE), Sanofi (FR), Novo Nordisk (DK), Johnson & Johnson (US) are some of the major participants in the global market.

Gestational Diabetes Market Trends

The Gestational Diabetes Market is currently experiencing notable transformations driven by various factors. Increasing awareness regarding maternal health and the implications of gestational diabetes on both mothers and infants appears to be a primary catalyst for growth. Healthcare providers are emphasizing the importance of early diagnosis and management, which may lead to improved outcomes.

Furthermore, advancements in medical technology, including continuous glucose monitoring systems and telehealth services, seem to enhance patient engagement and adherence to treatment protocols. This evolving landscape suggests a shift towards more personalized care, potentially improving the quality of life for affected individuals. In addition, the rising prevalence of obesity and sedentary lifestyles among pregnant women is likely to contribute to the demand for effective management solutions within the Gestational Diabetes Market.

As healthcare systems adapt to these challenges, there is a growing focus on preventive measures and educational programs aimed at reducing risk factors. The integration of lifestyle modifications, nutritional counseling, and psychological support into treatment plans may further shape the market dynamics. Overall, the Gestational Diabetes Market appears poised for continued expansion as stakeholders recognize the importance of comprehensive care strategies.

Technological Advancements in Monitoring

The emergence of innovative technologies for monitoring blood glucose levels is reshaping the Gestational Diabetes Market. Devices such as continuous glucose monitors are becoming increasingly popular, allowing for real-time tracking and management of glucose levels. This trend indicates a shift towards more proactive and personalized care, enhancing patient outcomes.

According to the World Health Organization, over 120 countries have implemented digital health strategies, accelerating the adoption of advanced monitoring technologies such as connected glucose monitoring systems.

Increased Focus on Preventive Care

There is a growing emphasis on preventive care strategies within the Gestational Diabetes Market. Healthcare providers are prioritizing education and lifestyle interventions to mitigate risk factors associated with gestational diabetes. This trend suggests a proactive approach to maternal health, potentially reducing the incidence of the condition.

The World Health Organization reports that a significant proportion of diabetes cases, including gestational diabetes, are linked to modifiable risk factors such as obesity and physical inactivity, supporting the need for preventive healthcare strategies.

Integration of Telehealth Services

The integration of telehealth services into the management of gestational diabetes is gaining traction. This trend reflects a broader shift towards remote healthcare solutions, enabling patients to receive guidance and support from healthcare professionals without the need for in-person visits. Such services may enhance accessibility and convenience for expectant mothers.

According to the World Health Organization, the majority of countries now utilize telemedicine or e-health services, significantly improving access to maternal and chronic disease care.

Gestational Diabetes Market Drivers

Advancements in Medical Technology

Technological innovations play a crucial role in shaping the Gestational Diabetes Market. The development of advanced monitoring devices, such as continuous glucose monitors and mobile health applications, has transformed the way gestational diabetes is managed. These technologies enable real-time tracking of blood glucose levels, allowing for timely interventions and personalized care plans.

Furthermore, the integration of artificial intelligence in data analysis enhances the accuracy of risk assessments and treatment recommendations. As these technologies become more accessible and affordable, they are expected to drive market growth by improving patient outcomes and increasing adherence to treatment protocols. The ongoing evolution of medical technology thus presents a promising avenue for expansion within the gestational diabetes sector.

Increase in Healthcare Expenditure

The rise in healthcare expenditure is a significant factor influencing the Gestational Diabetes Market. As countries allocate more resources to maternal health, there is a corresponding increase in funding for gestational diabetes management programs. This trend is evident in various regions, where investments in healthcare infrastructure and services are prioritized. Enhanced funding allows for improved access to screening, treatment options, and educational initiatives, which are essential for managing gestational diabetes effectively.

Furthermore, as healthcare systems evolve to accommodate the needs of pregnant women, the demand for gestational diabetes products and services is likely to grow. This increase in expenditure reflects a broader commitment to improving maternal health outcomes and addressing the challenges posed by gestational diabetes.

Policy Changes and Healthcare Reforms

Recent policy changes and healthcare reforms are shaping the landscape of the Gestational Diabetes Market. Governments and health organizations are increasingly recognizing the importance of maternal health, leading to enhanced coverage for gestational diabetes screening and management. These reforms often include provisions for subsidized access to necessary medications, monitoring devices, and educational resources.

As a result, more women are likely to seek care and treatment for gestational diabetes, thereby expanding the market. Additionally, policies that promote preventive care and early intervention are expected to further drive demand for gestational diabetes solutions, as they emphasize the importance of managing this condition effectively to prevent long-term health complications.

Rising Incidence of Gestational Diabetes

The increasing prevalence of gestational diabetes is a primary driver of the Gestational Diabetes Market. Recent data indicates that approximately 6 to 9% of pregnant women are diagnosed with this condition, a figure that has been steadily rising. This trend is attributed to various factors, including the growing rates of obesity and sedentary lifestyles among women of childbearing age.

As awareness of gestational diabetes expands, healthcare providers are more vigilant in screening and diagnosing this condition, leading to a heightened demand for management solutions. Consequently, the market for gestational diabetes products and services is likely to experience significant growth, as both healthcare professionals and patients seek effective interventions to manage this increasingly common condition.

Growing Awareness and Education Initiatives

The rising awareness surrounding gestational diabetes is significantly influencing the Gestational Diabetes Market. Educational campaigns aimed at both healthcare providers and expectant mothers are crucial in promoting understanding of the condition and its potential complications. Initiatives by health organizations and non-profits have led to increased screening and early diagnosis, which are essential for effective management.

As more women become informed about the risks associated with gestational diabetes, there is a corresponding increase in demand for educational resources and management tools. This heightened awareness not only fosters proactive health measures but also drives the market for gestational diabetes products, as patients seek reliable solutions to manage their health during pregnancy.

Market Segment Insights

By Diagnosis Type: Oral Glucose Tolerance Test (Largest) vs. Hemoglobin A1c Test (Fastest-Growing)

In the Gestational Diabetes Market, the Oral Glucose Tolerance Test (OGTT) currently holds the largest market share as the most widely utilized method for diagnosing gestational diabetes. This method requires a two-hour fasting period after consuming a glucose solution, making it a reliable choice for clinicians. On the other hand, the Hemoglobin A1c Test, although smaller in market share, has been gaining traction due to its convenience and ability to provide average blood sugar levels over the past three months. Growth trends in the Gestational Diabetes segment are being driven by increasing awareness about the condition and the rising prevalence of diabetes in pregnant women. The Hemoglobin A1c Test is rapidly emerging as an alternative due to its minimally invasive nature and shorter turnaround time for results. As healthcare providers seek to enhance patient experience and streamline diagnostic processes, tests like the Hemoglobin A1c are anticipated to witness significant growth in adoption rates in the coming years.

Oral Glucose Tolerance Test (Dominant) vs. Hemoglobin A1c Test (Emerging)

The Oral Glucose Tolerance Test is the dominant diagnostic method for gestational diabetes, primarily due to its extensive validation and recognition in clinical guidelines. It involves a detailed assessment of glucose metabolism, which is crucial for identifying women at high risk. In contrast, the Hemoglobin A1c Test is emerging as a promising alternative, primarily benefiting from its non-fasting requirement and ability to accumulate historical data on glucose levels, thus providing a comprehensive overview of a patient's glycemic control over time. The growing preference for less invasive tests among patients and healthcare providers is propelling the A1c Test towards becoming a favored diagnostic tool within clinical practices.

By Treatment Type: Dietary Changes (Largest) vs. Insulin Therapy (Fastest-Growing)

In the Gestational Diabetes Market, the treatment type segment showcases a diverse distribution among various values. Dietary Changes lead the Gestational Diabetes Market as the largest segment, as it emphasizes lifestyle intervention, including nutritional modifications that are essential for managing blood glucose levels. Insulin Therapy follows, marked as the fastest-growing segment due to an increase in prevalence rates of gestational diabetes and a recognized necessity for insulin in cases where dietary changes are insufficient to control glucose levels.

Dietary Changes (Dominant) vs. Insulin Therapy (Emerging)

Dietary Changes are characterized by a focus on personalized nutrition plans that cater to the specific needs of pregnant women. This dominant approach empowers patients by emphasizing sustainable lifestyle changes that manage gestational diabetes effectively. On the other hand, Insulin Therapy is emerging rapidly in Gestational Diabetes Market, stemming from advancements in diabetes care and technology. It is often prescribed when treatments like dietary changes fall short, indicating an increased reliance on pharmacological approaches. The efficacy of insulin as a treatment option reinforces its market position, driving innovation and competitive strategies among manufacturers to deliver safe and effective solutions.

By Risk Factor: Obesity (Largest) vs. Age (Fastest-Growing)

In the Gestational Diabetes Market, the risk factors showcase a diverse landscape, with obesity being the largest segment. This risk factor significantly contributes to the prevalence of gestational diabetes, as the rising obesity rates among pregnant women are closely tied to increased incidence. Following obesity, factors such as family history and previous gestational diabetes play crucial roles, but their market shares are comparatively smaller.

Obesity (Dominant) vs. Age (Emerging)

Obesity remains the dominant risk factor within the market share, attributed to lifestyle changes and increasing rates of obesity among women of childbearing age. This segment is characterized by various health implications that accompany obesity, such as insulin resistance. Younger maternal age, while historically seen as a protective factor, is emerging as a significant risk due to shifts in health behaviors. This trend suggests that younger mothers may face rising challenges related to gestational diabetes as healthcare awareness improves and screening becomes more robust.

By Patient Age: Adults (Largest) vs. Teenagers (Fastest-Growing)

In the Gestational Diabetes Market, the patient age segment is predominantly represented by adults, who make up a significant share of diagnosed individuals. Adults face heightened risk factors associated with gestational diabetes, such as obesity and advanced maternal age, contributing to a sizeable market presence. Teenagers, while a smaller segment, are also becoming increasingly relevant as awareness grows around early onset cases, reflecting a unique demographic shift in the Gestational Diabetes Market.

Adults (Dominant) vs. Teenagers (Emerging)

Adults represent the dominant segment in the market share. This group is often characterized by rising obesity rates and lifestyle factors that contribute to higher incidence of gestational diabetes. Clinical focus is increasingly directed towards maternal health education, promoting screenings and preventative measures within this age group. On the other hand, teenagers are emerging as a growing concern. This segment typically comprises younger pregnant women who may encounter unique challenges relating to gestational diabetes. The increasing prevalence of obesity in this demographic indicates a need for targeted interventions and healthcare support, establishing their importance in future market strategies.

Get more detailed insights about Gestational Diabetes Market

Request Free Sample

Regional Insights

North America : Leading Market for Innovation

North America leads in the Gestational Diabetes Market Size, accounting for over 45.23% of the global revenue in 2024. The region benefits from advanced healthcare infrastructure, increasing awareness of gestational diabetes, and supportive government regulations. The rising prevalence of diabetes among pregnant women is driving demand for innovative monitoring and treatment solutions, further bolstered by initiatives aimed at improving maternal health outcomes.

The United States is the leading country in Gestational Diabetes Market, followed by Canada. Key players such as Abbott Laboratories, Medtronic, and Dexcom are heavily investing in research and development to enhance their product offerings. The competitive landscape is characterized by a focus on technological advancements, including continuous glucose monitoring systems and mobile health applications, which are gaining traction among healthcare providers and patients alike.

Europe : Emerging Market with Growth Potential

Europe Gestational Diabetes Market was valued at USD 0.60 billion in 2024, making it the second-largest regional market with a 30% share. The increasing incidence of gestational diabetes, coupled with rising healthcare expenditure and awareness campaigns, is driving market expansion. Regulatory bodies are also implementing guidelines to improve screening and management practices, which are expected to further enhance market growth in the coming years.

Germany and France are the leading countries in this region, with a strong presence of key players like Roche Diagnostics and Sanofi. The competitive landscape is evolving, with companies focusing on innovative solutions and partnerships to enhance their market position. The emphasis on preventive healthcare and patient education is also shaping the market dynamics, making it a promising area for investment and development.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is emerging as a significant player in the gestational diabetes market, accounting for about 20% of the global share. Factors such as increasing urbanization, lifestyle changes, and rising obesity rates are contributing to the growing prevalence of gestational diabetes. Governments are also implementing policies to enhance maternal healthcare, which is expected to drive demand for diabetes management solutions in the region. Countries like China and India are at the forefront of this Gestational Diabetes Market, with a growing number of healthcare providers focusing on diabetes management.

The competitive landscape includes key players like Becton Dickinson and Ascensia Diabetes Care, who are actively working to introduce innovative products tailored to local needs. The region's diverse healthcare systems present both challenges and opportunities for market growth, making it a focal point for future investments.

Middle East and Africa : Untapped Market with Challenges

The Middle East and Africa region represents an untapped market for gestational diabetes management, holding approximately 5% of the global share. The rising prevalence of diabetes, coupled with limited access to healthcare services, poses challenges for market growth. However, increasing awareness and government initiatives aimed at improving maternal health are expected to drive demand for diabetes management solutions in the coming years.

Countries like South Africa and the UAE are leading the way in addressing gestational diabetes, with a growing focus on healthcare infrastructure development. Key players are beginning to enter this Gestational Diabetes Market, recognizing the potential for growth. The competitive landscape is still developing, with opportunities for innovative solutions and partnerships to enhance healthcare delivery and patient outcomes in this region.

Gestational Diabetes Market Regional Image

Key Players and Competitive Insights

The Global Gestational Diabetes Market is a critical segment within the broader healthcare sector, focusing on the diagnosis, management, and treatment of gestational diabetes mellitus (GDM). This Gestational Diabetes Market has gained significant traction due to the increasing prevalence of diabetes among pregnant women, heightened awareness regarding maternal and fetal health, and advancements in medical technologies. As healthcare providers pivot towards tailored solutions for managing GDM, competition within this market intensifies.

The landscape is characterized by a blend of pharmaceutical and biotechnology companies offering medications, monitoring technologies, and educational resources aimed at ensuring better patient outcomes. The growing number of partnerships and collaborations among key players to enhance product offerings and expand market reach further exemplifies the dynamic nature of this sector.

Merck and Co stand out in the competitive landscape of the Global Gestational Diabetes Market due to its robust research and development capabilities and a strong portfolio of diabetes-related products. The company's commitment to innovation and its extensive experience in diabetes care have positioned it as a key player in this space. Merck and Co's focus on developing medications and solutions specifically targeting diabetes management has reinforced its market presence.

The integration of advanced technologies in their products further strengthens their offerings, providing healthcare professionals with efficient tools to address the complexities of gestational diabetes. Their strategic initiatives, including partnerships with healthcare providers and academic institutions, empower them to enhance patient management while solidifying their competitive edge.

Abbott Laboratories is another prominent contributor within the Global Gestational Diabetes Market, known for its comprehensive approach to addressing diabetes care. The company offers a range of innovative products and services designed to monitor and manage blood glucose levels in pregnant women with gestational diabetes. Abbott's continuous investment in research and development has led to the launch of cutting-edge monitoring systems and insulin delivery solutions that cater specifically to the needs of this demographic.

Their Global presence, combined with a strong distribution network, enhances accessibility to their products. Furthermore, Abbott Laboratories has actively engaged in mergers and acquisitions to bolster its capabilities and broaden its portfolio, ensuring that it remains at the forefront of diabetes management solutions. The combination of their high-quality products, strong market presence, and strategic initiatives has solidified Abbott's position as a formidable player in the Gestational Diabetes Market space.

Key Companies in the Gestational Diabetes Market include

Recent Industry Developments

Recent developments in the Global Gestational Diabetes Market indicate a growing emphasis on technological advancements and patient care. Companies like Abbott Laboratories and Novo Nordisk are expanding their product lines to include innovative glucose monitoring systems and insulin therapy options designed specifically for gestational diabetes management.

In September 2023, Merck and Co announced a strategic partnership aimed at enhancing their metabolic disease portfolio, focusing on gestational diabetes. Additionally, in July 2023, Roche launched a new digital health solution to help expectant mothers manage their diabetes more effectively. Notably, Johnson and Johnson reported a significant increase in market valuation due to their recent advancements in continuous glucose monitoring technologies.

Companies like Medtronic and Eli Lilly and Company continue to invest heavily in Research and Development to meet the rising demand, particularly in regions with increasing prevalence rates. The Gestational Diabetes Market also saw a surge in collaborations, with Boehringer Ingelheim and AstraZeneca exploring joint ventures to develop combination therapies, reflecting a broader industry trend toward integrated treatment approaches. Over the last couple of years, the global focus on maternal health and diabetes has intensified, resulting in substantial investments from these key players within the industry.

Future Outlook

Gestational Diabetes Market Future Outlook

The Gestational Diabetes Market size is projected to reach USD 3.704 Billion by 2035, growing at a CAGR of 5.81%, driven by rising prevalence, increased awareness, and advancements in treatment options.

New opportunities lie in:

Development of telehealth platforms for remote monitoring and support. Launch of personalized nutrition plans tailored for gestational diabetes management. Investment in AI-driven predictive analytics for risk assessment and intervention.

By 2035, the Gestational Diabetes Market is expected to achieve substantial growth and innovation.

Market Segmentation

Gestational Diabetes Market Patient Age Outlook

Teenagers
Adults
Elderly

Gestational Diabetes Market Risk Factor Outlook

Obesity
Family History
Age
Previous Gestational Diabetes

Gestational Diabetes Market Diagnosis Type Outlook

Oral Glucose Tolerance Test
Fasting Blood Sugar Test
Random Blood Sugar Test
Hemoglobin A1c Test

Gestational Diabetes Market Treatment Type Outlook

Dietary Changes
Insulin Therapy
Oral Medications
Physical Activity

Report Scope

MARKET SIZE 2024	1.99(USD Billion)
MARKET SIZE 2025	2.106(USD Billion)
MARKET SIZE 2035	3.704(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.81% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Abbott Laboratories (US), Roche Diagnostics (CH), Becton Dickinson and Company (US), Medtronic (US), Dexcom (US), Ascensia Diabetes Care (DE), Sanofi (FR), Novo Nordisk (DK), Johnson & Johnson (US)
Segments Covered	Diagnosis Type, Treatment Type, Risk Factor, Patient Age, Regional
Key Market Opportunities	Integration of digital health solutions enhances monitoring and management in the Gestational Diabetes Market.
Key Market Dynamics	Rising prevalence of gestational diabetes drives demand for innovative monitoring technologies and personalized treatment solutions.
Countries Covered	North America, Europe, APAC, South America, MEA

Market Highlights

Gestational Diabetes Companies

Frequently Asked Questions

What is the projected market valuation for the Gestational Diabetes Market in 2035?

The projected market valuation for the Gestational Diabetes Market in 2035 is expected to reach 3.704 USD Billion.

What was the market valuation of the Gestational Diabetes Market in 2024?

The market valuation of the Gestational Diabetes Market was 1.99 USD Billion in 2024.

What is the expected CAGR for the Gestational Diabetes Market during the forecast period 2025 - 2035?

The expected CAGR for the Gestational Diabetes Market during the forecast period 2025 - 2035 is 5.81%.

Which companies are considered key players in the Gestational Diabetes Market?

Key players in the Gestational Diabetes Market include Abbott Laboratories, Roche Diagnostics, Becton Dickinson and Company, and Medtronic.

What are the main diagnosis types contributing to the Gestational Diabetes Market?

The main diagnosis types include Oral Glucose Tolerance Test, Fasting Blood Sugar Test, Random Blood Sugar Test, and Hemoglobin A1c Test.

What is the market value range for the Oral Glucose Tolerance Test segment?

The market value range for the Oral Glucose Tolerance Test segment is between 0.8 and 1.5 USD Billion.

How do dietary changes impact the Gestational Diabetes treatment market?

Dietary changes are projected to contribute between 0.6 and 1.1 USD Billion to the treatment market.

What risk factors are associated with Gestational Diabetes?

Key risk factors include obesity, family history, age, and previous gestational diabetes, with valuations ranging from 0.29 to 1.5 USD Billion.

What age groups are primarily affected by Gestational Diabetes?

The primary age groups affected include teenagers, adults, and the elderly, with adults representing a market value range of 1.2 to 2.2 USD Billion.

What treatment types are expected to grow in the Gestational Diabetes Market?

Treatment types expected to grow include insulin therapy, oral medications, and physical activity, with insulin therapy valued between 0.7 and 1.3 USD Billion.

Author

Author

Vikita Thakur

Senior Research Analyst

She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.

Co-Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of maternal health databases, peer-reviewed obstetric and endocrinology journals, clinical guidelines, and authoritative diabetes and women's health organizations. Key sources included the US Centers for Disease Control and Prevention (CDC) Division of Diabetes Translation, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH), US Food & Drug Administration (FDA) Center for Devices and Radiological Health, European Medicines Agency (EMA), International Diabetes Federation (IDF) Diabetes Atlas, World Health Organization (WHO) Department of Maternal Health, American College of Obstetricians and Gynecologists (ACOG), International Federation of Gynecology and Obstetrics (FIGO), American Diabetes Association (ADA) Standards of Care, International Association of Diabetes and Pregnancy Study Groups (IADPSG), Healthcare Cost and Utilization Project (HCUP), National Vital Statistics System (NVSS), CDC National Center for Health Statistics, OECD Health Statistics, Eurostat Health Database, and national health ministry reports from key markets. These sources were used to collect gestational diabetes prevalence statistics, maternal health policy data, diagnostic protocol adoptions, screening guideline updates, insulin and oral hypoglycemic agent approval data, clinical outcome studies, demographic pregnancy trends, and competitive landscape analysis for continuous glucose monitors, blood glucose meters, insulin pumps, and lancet devices.

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Medical Affairs, regulatory strategy chiefs, and commercial directors from diabetes device manufacturers (CGM systems, blood glucose monitors, insulin pumps), pharmaceutical companies (insulin, oral hypoglycemic agents), and in-vitro diagnostic companies. Maternal-fetal medicine specialists, board-certified endocrinologists, obstetricians and gynecologists, certified diabetes educators, maternal health clinic directors, and procurement lead from hospitals, specialty maternal care centers, and obstetric clinics composed demand-side sources. Primary research has confirmed the product pipeline timelines for next-generation CGMs and biosimilars, validated market segmentation across oral glucose tolerance tests and continuous monitoring systems and gathered insights on clinical adoption patterns of point-of-care testing, insulin therapy protocols, reimbursement dynamics for maternal diabetes management, and patient compliance trends across different risk factor categories.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (40%), Europe (25%), Asia-Pacific (22%), Rest of World (13%)

Market Size Estimation

Global market valuation was derived through revenue mapping, device shipment analysis, and therapy adoption rates. The methodology included:

Identification of 50+ key manufacturers and service providers across diabetes diagnostics, therapeutic devices, and pharmaceutical interventions in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Product mapping across continuous glucose monitoring systems, blood glucose meters, insulin pumps, lancets and strips, insulin therapies (rapid-acting, long-acting, premixed), oral hypoglycemic agents (metformin, glyburide), and dietary management programs

Analysis of reported and modeled annual revenues specific to gestational diabetes and maternal glucose management portfolios

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (device volume × ASP by country/region, procedure volumes for OGTT screenings, insulin prescription volumes) and top-down (manufacturer revenue validation, therapy market share analysis) approaches to derive segment-specific valuations for diagnosis types (OGTT, HbA1c, CGM), treatment modalities (insulin therapy, oral medications, dietary interventions), and risk factor categories (obesity-related, family history, advanced maternal age)

Certified Researchers

Customize Report

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035